TX-001HR is associated with a clinically meaningful effect on severity of moderate to severe vasomotor symptoms in the REPLENISH trial.

Constantine, Ginger D; Simon, James A; Kaunitz, Andrew M; Pickar, James H; Revicki, Dennis A; Graham, Shelli; Bernick, Brian; Mirkin, Sebastian

Constantine, Ginger D; Simon, James A; Kaunitz, Andrew M; Pickar, James H; Revicki, Dennis A; Graham, Shelli; Bernick, Brian; Mirkin, Sebastian.

Afiliação

Constantine GD; EndoRheum Consultants, LLC, Malvern, PA.
Simon JA; IntimMedicine Specialists, Washington, DC.
Kaunitz AM; University of Florida College of Medicine-Jacksonville, Jacksonville, FL.
Pickar JH; Columbia University Medical Center, New York, NY.
Revicki DA; KMITL Faculty of Medicine, Bangkok, Thailand.
Graham S; Patient-Centered Research, Evidera, Bethesda, MD.
Bernick B; TherapeuticsMD, Boca Raton, FL.
Mirkin S; TherapeuticsMD, Boca Raton, FL.

Menopause ; 27(11): 1236-1241, 2020 11.

Article em En | MEDLINE | ID: mdl-33110039

Assuntos

Pós-Menopausa; Progesterona; Método Duplo-Cego; Estradiol; Feminino; Fogachos/tratamento farmacológico; Humanos; Resultado do Tratamento

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Progesterona / Pós-Menopausa Tipo de estudo: Clinical_trials / Diagnostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google